David Mountcastle Sells 600 Shares of Privia Health Group (NASDAQ:PRVA) Stock

Privia Health Group, Inc. (NASDAQ:PRVAGet Free Report) CFO David Mountcastle sold 600 shares of the business’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $27.57, for a total transaction of $16,542.00. Following the completion of the sale, the chief financial officer directly owned 186,128 shares in the company, valued at approximately $5,131,548.96. This trade represents a 0.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Mountcastle also recently made the following trade(s):

  • On Thursday, July 2nd, David Mountcastle sold 24,734 shares of Privia Health Group stock. The shares were sold at an average price of $27.50, for a total value of $680,185.00.
  • On Friday, June 26th, David Mountcastle sold 17,196 shares of Privia Health Group stock. The shares were sold at an average price of $25.18, for a total value of $432,995.28.
  • On Monday, May 11th, David Mountcastle sold 3,385 shares of Privia Health Group stock. The stock was sold at an average price of $22.60, for a total transaction of $76,501.00.
  • On Monday, May 4th, David Mountcastle sold 1,206 shares of Privia Health Group stock. The shares were sold at an average price of $25.00, for a total transaction of $30,150.00.
  • On Friday, May 1st, David Mountcastle sold 7,179 shares of Privia Health Group stock. The stock was sold at an average price of $25.03, for a total transaction of $179,690.37.

Privia Health Group Trading Down 1.0%

Shares of NASDAQ:PRVA opened at $27.49 on Friday. The company has a 50-day moving average price of $23.76 and a 200-day moving average price of $23.14. The company has a market cap of $3.46 billion, a price-to-earnings ratio of 171.82, a price-to-earnings-growth ratio of 2.20 and a beta of 0.83. Privia Health Group, Inc. has a 12 month low of $18.77 and a 12 month high of $27.86.

Hedge Funds Weigh In On Privia Health Group

Institutional investors have recently made changes to their positions in the company. Bayban bought a new stake in shares of Privia Health Group in the fourth quarter valued at about $26,000. Hantz Financial Services Inc. grew its holdings in Privia Health Group by 456.2% during the 4th quarter. Hantz Financial Services Inc. now owns 1,129 shares of the company’s stock worth $27,000 after acquiring an additional 926 shares in the last quarter. Global Retirement Partners LLC increased its position in Privia Health Group by 579.8% during the 4th quarter. Global Retirement Partners LLC now owns 1,584 shares of the company’s stock valued at $38,000 after purchasing an additional 1,351 shares during the period. Harbor Investment Advisory LLC purchased a new position in Privia Health Group during the 2nd quarter valued at about $69,000. Finally, Canada Pension Plan Investment Board raised its holdings in shares of Privia Health Group by 48.0% in the 2nd quarter. Canada Pension Plan Investment Board now owns 3,700 shares of the company’s stock valued at $85,000 after purchasing an additional 1,200 shares in the last quarter. Hedge funds and other institutional investors own 94.48% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on PRVA shares. Zacks Research downgraded Privia Health Group from a “hold” rating to a “strong sell” rating in a research report on Tuesday. Canaccord Genuity Group reduced their price target on shares of Privia Health Group from $35.00 to $34.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Evercore set a $26.00 price objective on shares of Privia Health Group in a research report on Wednesday, April 8th. Weiss Ratings upgraded shares of Privia Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, July 2nd. Finally, Barclays reduced their target price on shares of Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 26th. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $31.15.

Check Out Our Latest Research Report on PRVA

Privia Health Group News Roundup

Here are the key news stories impacting Privia Health Group this week:

Privia Health Group Company Profile

(Get Free Report)

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.

Read More

Insider Buying and Selling by Quarter for Privia Health Group (NASDAQ:PRVA)

Receive News & Ratings for Privia Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Privia Health Group and related companies with MarketBeat.com's FREE daily email newsletter.